Ekso Bionics (EKSO) CFO adds 1,308 common shares through 401(k) plan

Rhea-AI Filing Summary

Ekso Bionics Holdings, Inc. Chief Financial Officer Jerome Wong reported an open-market purchase of common stock through a 401(k) plan. He acquired 1,308 shares on March 16, 2026 at $11.85 per share, held indirectly via a 401(k) account under the company’s matching contribution program.

Following this transaction, he indirectly held 4,184 shares through the 401(k) and directly held 24,771 shares of common stock. A prior 1-for-15 reverse stock split effective on June 2, 2025 is reflected in the reported share amounts.

Insider Trade Summary

Net Buyer: 1,308 shares ($15,500)

Net Buy 2 txns

Insider Wong Jerome

Role Chief Financial Officer

Bought 1,308 shs ($15K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,308	$11.85	$15K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 4,184 shares (Indirect, By 401(k)); Common Stock — 24,771 shares (Direct)

Footnotes (1)

1. These shares of common stock were acquired in connection with the Issuer's 401(k) contribution matching program. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wong Jerome

(Last) (First) (Middle)

101 GLACIER POINT

SUITE A

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EKSO BIONICS HOLDINGS, INC. [ EKSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		P		1,308(1)	A	$11.85	4,184(2)	I	By 401(k)
Common Stock								24,771(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were acquired in connection with the Issuer's 401(k) contribution matching program.

2. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

	/s/ Jerome Wong	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Ekso Bionics (EKSO) report for CFO Jerome Wong?

Ekso Bionics reported that CFO Jerome Wong bought common stock through a 401(k) plan. He acquired 1,308 shares of Ekso Bionics common stock in an open-market transaction recorded in his 401(k), showing an incremental increase in his indirect share ownership.

How many Ekso Bionics (EKSO) shares did the CFO buy and at what price?

CFO Jerome Wong purchased 1,308 shares of Ekso Bionics common stock at $11.85 per share. The acquisition occurred on March 16, 2026 and was executed as an open-market purchase associated with the company’s 401(k) contribution matching program for his retirement account.

How many Ekso Bionics (EKSO) shares does the CFO hold after this Form 4 transaction?

After the reported transaction, CFO Jerome Wong indirectly held 4,184 shares of Ekso Bionics through his 401(k) and directly held 24,771 shares. These figures together show his combined direct and indirect ownership of the company’s common stock following the March 16, 2026 purchase.

What is the nature of ownership for the Ekso Bionics (EKSO) shares bought by the CFO?

The 1,308 shares acquired are held indirectly by CFO Jerome Wong “by 401(k).” A footnote explains they were obtained through Ekso Bionics’ 401(k) contribution matching program, meaning they are part of his retirement plan rather than directly registered in his own name.

How did Ekso Bionics’ reverse stock split affect the CFO’s reported Form 4 shares?

Ekso Bionics completed a 1-for-15 reverse stock split of its common stock effective June 2, 2025. The Form 4 notes that all share amounts reported for CFO Jerome Wong have been adjusted to reflect this reverse split, ensuring the holdings and transaction figures match the post-split share structure.

Does the Ekso Bionics (EKSO) Form 4 show any derivative or option activity for the CFO?

The Form 4 data show no derivative transactions for CFO Jerome Wong in this filing. The derivative summary is empty, and transaction details only reference Ekso Bionics common stock, indicating the reported activity relates solely to share purchases and holdings, not options or other derivative securities.